Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Science club formation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by whisky11on Mar 09, 2021 1:45pm
121 Views
Post# 32753920

RE:Science club formation

RE:Science club formationMinimumDamage]To anyone that thinks this is ''good'' news is pure absurdity. Claritas lauching the nasal spray and the syringe before even having a competent team to run this sh1t show? Yes, this is actually worthy of left and right Scooby-doo spaghetti running in every directions. But like they say GLTA!!!!!!!!!   MOONSHOT incoming

whisky11: why  you're talking about so many things. Wouldn't be better if you leave the Scooby Doo in spaghetti for another post? How we can answer to your post when you sound like idiot?
 Now to the business, nasal spray and syringe is just delivery system/tool what is in there that what matters. This medicine has to be delivered to two years old and hundred years old ,
200 pounds and 100 pounds patient. To the person with pneumonia or the guy with the  damaged lungs because of exposure to asbestos. If it's working it's hundred dollars stock.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities